Potdar P, Monteiro F
Department of Molecular Medicine and Biology, Jaslok Hospital and Research Centre , 15, Dr. G. Deshmukh Road, Mumbai- 400026, Maharashtra, India.
J Stem Cells Regen Med. 2012 Nov 26;8(3):190-7. doi: 10.46582/jsrm.0803012. eCollection 2012.
Breast Cancer (BC) is a heterogeneous disease and arises from breast cancer initiating stem cell population in the tumor and these cells are resistant to cancer therapies. Thus identifying this cell type within the tumor clone is an important area of research to understand the mechanism of breast cancer development. Recently, our laboratory has isolated and characterized Human breast cancer mesenchymal stem cells (hBCMSCs) from human breast cancer and showed the heterogeneity of these cells existing in the tumor. Therefore, our present objective is to use this model system to identify, localize and define specific breast cancer initiating cells (BCICs) from the heterogeneous population of hBCMSCs cell line developed in our laboratory. Localization of specific cell types can be done by using specific cancer marker antibodies using Immunofluorescence microscopy. In this study we have used FITC labeled specific cancer antibodies i.e. p53, Rb1, Hras, Ki67, EGFR, GST, ETS1 and ATF2 to localize BCICs in this population of cells. Our results have demonstrated that few cells among many of the BC cells gave fluorescence with specific cancer antibody indicating that these cell types are BCICs that may be responsible for supporting the growth of other cell type to form tumors. The Phase Contrast Microscopy clearly showed giant cells with enlarged nucleus and scanty cytoplasm associated with many cytoplasmic granules. It also indicates that these cells are mainly responsible for supporting proliferation of surrounding cells that form a part of the BC tumor. We have further hypothesized that molecular profiling of these tumor cells will open a new avenue of molecular targeted therapies for Breast Cancer patients even at an advanced stage of disease.
乳腺癌(BC)是一种异质性疾病,起源于肿瘤中的乳腺癌起始干细胞群体,这些细胞对癌症治疗具有抗性。因此,在肿瘤克隆中识别这种细胞类型是理解乳腺癌发展机制的一个重要研究领域。最近,我们实验室从人类乳腺癌中分离并鉴定了人类乳腺癌间充质干细胞(hBCMSCs),并显示了这些细胞在肿瘤中存在的异质性。因此,我们目前的目标是利用这个模型系统,从我们实验室建立的hBCMSCs细胞系的异质群体中识别、定位和定义特定的乳腺癌起始细胞(BCICs)。特定细胞类型的定位可以通过使用免疫荧光显微镜的特异性癌症标志物抗体来完成。在这项研究中,我们使用了异硫氰酸荧光素(FITC)标记的特异性癌症抗体,即p53、Rb1、Hras、Ki67、表皮生长因子受体(EGFR)、谷胱甘肽S转移酶(GST)、ETS1和活化转录因子2(ATF2),来定位这群细胞中的BCICs。我们的结果表明,许多BC细胞中的少数细胞与特异性癌症抗体产生荧光,表明这些细胞类型是BCICs,可能负责支持其他细胞类型的生长以形成肿瘤。相差显微镜清楚地显示了细胞核增大、细胞质稀少并伴有许多细胞质颗粒的巨大细胞。这也表明这些细胞主要负责支持形成BC肿瘤一部分的周围细胞的增殖。我们进一步推测,这些肿瘤细胞的分子谱分析将为乳腺癌患者开辟一条新的分子靶向治疗途径,即使在疾病的晚期也是如此。